No Data
No Data
Leerink Partners Upgrades AN2 Therapeutics to Outperform
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.
Express News | Octagon Capital Advisors LP Reports 10.1% Passive Stake in AN2 Therapeutics as of June 13 - SEC Filing
Leerink Partners Upgrades AN2 Therapeutics(ANTX.US) to Buy Rating, Maintains Target Price $5
Leerink Partners analyst Joseph Schwartz upgrades $AN2 Therapeutics(ANTX.US)$ to a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 41.5%
Optimistic Outlook for AN2 Therapeutics' Epetraborole Despite Initial Concerns
Express News | AN2 Therapeutics Inc : Leerink Partners Raises to Outperform From Market Perform
12 Health Care Stocks Moving In Friday's After-Market Session
GainersKineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 1
No Data
NVDAvsTSLA : No one knows the results only the company themselves
TrytosaveabitOP NVDAvsTSLA: That’s why I said ( upcoming ) meaning later when they release the results/data! If it’s good it could be a catalyst. Hehehe
NVDAvsTSLA TrytosaveabitOP: Agree. Back to $20 is easy once the tests are good
TrytosaveabitOP NVDAvsTSLA: That would be a great thing to see! GL to ya![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)